Kaufmann 2006.

Methods	Randomised, placebo controlled cross‐over study
Participants	30 participants with m.3243A>G
Interventions	25mg/kg/day of dichloracetate for 12 months
Outcomes	GATE, lactate measurements in venous blood, CSF and measured by 1H‐MRS. Nerve conduction tests were used to monitor safety
Notes	No benefit The trial was discontinued due to peripheral nerve toxicity
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Based on a computer‐generated randomization list"
Allocation concealment (selection bias)	Low risk	"the research pharmacy at the University of Florida mailed study medication for each participant to the clinical investigators"
Incomplete outcome data (attrition bias) All outcomes	Low risk	Incomplete outcome data for some participants, although this was due to withdrawal of participants due to side‐effects in the DCA group, and early termination of the study
Selective reporting (reporting bias)	Low risk	All outcome measures were reported for all participants up to the termination of the trial
Other bias	Low risk	None identified
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"clinical researchers remained blinded to treatment assignment throughout the trial"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Participants were randomly assigned to start in either the DCA or placebo arm